Ipsen, a global biopharmaceutical company, is seeking novel and innovative leads to treat rare disease and rare neuroscience disease indications. A range of therapeutic areas and targets will be considered, but target diseases should be rare (&gt;1.5 per million, &lt;1 per 2,000). A range of mechanisms&#x2011;of&#x2011;action and classes of molecules are of interest, with a particular focus on small molecules, peptides, biologics, nucleic acids, RNA therapies (i.e. siRNAs) and antibody conjugates. Ipsen is open to a variety of drug delivery methods. <h3>Development Stage of Interest...</h3>

Ipsen are searching for innovative leads to treat rare diseases and rare neuroscience diseases.

Seeking Novel Leads in Rare Diseases and Neuroscience

Cumulus Oncology identifies and funds the progression of early-stage opportunities to develop novel differentiated anti-cancer therapies, with the aim of improving outcomes for cancer patients. They are interested in identifying and engaging with academics who have highly tumour-restricted antigens or monoclonal or multivalent antibodies that target them which have the potential for therapeutic activity in cancer. Approaches of Interest: <ul> <li>Novel monoclonal antibodies, bi- and / or tri-specific antibodies that bind highly tumour-restricted antigens which ...</li></ul>

Cumulus Oncology are are interested in identifying and engaging with academics who have monoclonal or multivalent antibodies that target highly tumour-restricted antigens which have the potential for therapeutic activity in cancer.

Novel Highly Tumour-restricted Antigens and Antibodies for Cancer Therapy

Astellas Pharma, a global pharmaceutical company with cutting-edge capabilities in drug development, wishes to engage with academic research and biopharma companies and assets that involve the use of in vivo direct reprogramming to achieve cell conversion/ transdifferentiation from one cell type to another functional type. Astellas is particularly interested in the direct reprogramming of cells to cell types related to the Central Nervous System, Lung, Heart, Kidney, Liver, Gut, Skin and Eye. Their goal is to discover therapeutic interventions that cure...

Astellas Pharma is seeking research related to direct reprogramming to achieve  transdifferentiation of cells to another functional type. 


Seeking Research and Technologies Related to in vivo Direct Reprogramming

A top five pharmaceutical company with a history of successful academic collaborations, wishes to identify novel methods that allow for the discovery or design of orally bioavailable peptides and/or peptides that can access intracellular targets through passive permeation, endocytosis or via transporters. Approaches of Interest <ul> <li>Peptides designed to be intrinsically permeable/orally bioavailable through rational design (e.g., cyclisation, incorporation of non-natural amino acids, etc), next generation conjugation or other innovative approaches</li> <li>Design of ...</li></ul>

A top five pharmaceutical company wishes to identify novel methods that allow for the discovery or design of orally bioavailable peptides and/or peptides that can access intracellular targets.

Orally Bioavailable Peptides and/or Peptide Therapeutics for Modulating Intracellular Targets

Asahi Kasei Pharma, a global pharmaceutical company, is seeking novel drug molecules and novel druggable targets in the treatment of chronic pain, as well as in vitro screening systems to identify novel targets for chronic pain. The team is interested in new compounds and targets that will provide therapeutic benefit in the following indications: neuropathic pain, nociceptive pain, nociplastic pain, cancer pain, postoperative pain and other intractable chronic pains. Approaches of interest: <ul> <li>Asahi Kasei Pharma is open to different modalities including small...</li></ul>

Asahi Kasei Pharma is focused on the discovery and development of new medicines that address unmet medical needs, particularly in the field of pain management.

Seeking Novel Druggable Targets and Drug Screening Systems in Chronic Pain

AstraZeneca, a global biopharmaceutical and biotechnology company, are looking to develop innovative approaches to obtain a more complete picture of the folding of short and long reads to reveal interactions that create unique, higher order folding structures. Therapeutic targeting of RNA is an important and growing field of drug discovery. However, progress has been limited by a lack of understanding of RNA tertiary structure, in particular, of druggable binding sites. AstraZeneca are seeking partners who can help develop AI/physics-based methodologies...

AstraZeneca is seeking AI/physics-based methodologies for predicting RNA tertiary structure and folding.

RNA Structure and Folding Prediction Guided by Innovative Technologies

A leading global mining company is looking to explore new applications for the mineral polyhalite. Polyhalite (K&#x2082;Ca&#x2082;Mg(SO&#x2084;)&#x2084;&#xB7;2H&#x2082;O) has been established as an efficient crop fertiliser when physically processed into powder, granular or chips forms for ease of application. However, research suggests polyhalite has potential in other applications outside of crop nutrition including the biosciences and in particular, animal feed and nutrition. Our client is interested in novel polyhalite applications in animal nutrition. Specifically, our client is keen to connect...

A leading global mining company is seeking to explore new applications for the mineral polyhalite.

Seeking Novel Applications for Polyhalite in Animal Nutrition

A multinational pharmaceutical company is seeking first-in-class novel/established drug targets for Targeted Protein Degradation (TPD), especially proteolysis-targeting chimeras (PROTACs) in oncology. Priority cancers of interest are biliary tract cancer, pancreatic cancer, non-small cell lung cancer (PD-L1 negative), prostate cancer (castration-resistant), urothelial cancer, acute myeloid leukaemia. Other cancers such as breast cancer (triple-negative), ovarian cancer (platinum-resistant), soft tissue sarcoma and diffuse large B-cell lymphoma are also of...

A global pharmaceutical company is seeking oncology drug targets exploiting targeted protein degradation.

Oncology Drug Targets Exploiting Targeted Protein Degradation (TPD)

A multinational pharmaceutical company is looking for novel technologies or methodologies that allow antibody-drug conjugation. Specifically, our client is interested in novel linker conjugation technologies for mAB conjugation with conventional small molecule drugs. Approaches should use novel methods that provide improved serum stability and physicochemical properties compared to conventional conjugation methods. Approaches of Interest <ul> <li>Novel approaches for cysteine residue conjugation in the hinge region of mAb that improve on stability/physicochemical...</li></ul>

A global pharmaceutical company is seeking novel technology for antibody-drug conjugation, to improve on conventional methods.

Engage with world leading R&D teams

Active campaigns

ico